Английская Википедия:CGP-7930
Материал из Онлайн справочника
Шаблон:Short description Шаблон:Drugbox
CGP-7930 was the first positive allosteric modulator of GABAB receptors described in literature.[1][2][3][4] CGP7930 is also a GABAA receptor positive allosteric modulator and a blocker of Potassium channels.[5]
CGP7930 was developed in Novartis and has been used extensively for scientific research. It has anxiolytic effects in animal studies,[6][7] and has a synergistic effect with GABAB agonists such as baclofen and GHB,[8][9] as well as reducing self-administration of alcoholic drinks and cocaine.[10][11]
References
